Dataset from An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients

The purpose of this study is to test if the vaccine is working well in COPD patients aged 40
to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather
further information on safety and immune response.

In the current study, COPD patients with a history of acute exacerbations will receive 2
doses of the investigational vaccine or placebo intramuscularly according to a 0, 2 month
vaccination schedule, in addition to standard care.

The effect of vaccination against two pathogens known to cause exacerbations (Non-typeable
Haemophilus influenza [NTHi] and Moraxella catarrhalis [Mcat]) will be evaluated at
pre-defined timepoints (scheduled study visits).

In addition to the scheduled study visits, additional study visit(s) and/ or phone contact(s)
will take place for each acute exacerbation of COPD occurring from first vaccination up to
study conclusion.